Adagene (ADAG) Total Non-Current Liabilities (2019 - 2025)

Adagene's (ADAG) quarterly Total Non-Current Liabilities came in at -$205.1 billion in Q4 2025, down 529515.03% year-on-year from N/an in Q4 2024, and down 529515.03% on a QoQ basis from $38.7 million in Q4 2024.

Adagene (ADAG) Total Non-Current Liabilities (2019 - 2025) Analysis & Trends

Adagene (ADAG) has 7 years of Total Non-Current Liabilities data on file, last reported at -$205.1 billion in Q4 2025.

  • On a quarterly basis, Total Non-Current Liabilities fell 529515.03% year-over-year to -$205.1 billion in Q4 2025; TTM through Dec 2025 was -$205.1 billion, a 529515.03% decrease from a year earlier, with the FY2025 full-year figure at -$205.1 billion, down 529515.03% from the prior year.
  • Total Non-Current Liabilities for Q4 2025 stood at -$205.1 billion, down from $38.7 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for ADAG reached as high as $45.2 million in Q4 2023 and fell as low as -$205.1 billion in Q4 2025.
  • Historically, Total Non-Current Liabilities has averaged -$36.4 billion across 5 years, with a median of -$13.8 billion in 2021.
  • Across the five-year window, Total Non-Current Liabilities surged 100.16% in 2023 and plunged 529515.03% in 2025, its largest moves.
  • Year by year, Total Non-Current Liabilities stood at $32.9 million in 2021, then slumped by 87289.64% to -$28.6 billion in 2022, then jumped by 100.16% to $45.2 million in 2023, then decreased by 14.22% to $38.7 million in 2024, then plunged by 529515.03% to -$205.1 billion in 2025.
  • Per Business Quant data, the three most recent Total Non-Current Liabilities figures were -$205.1 billion in Q4 2025, $38.7 million in Q4 2024, and $45.2 million in Q4 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 4.45 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 110.28 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 1.98 Bn
4 NuCana 279.75 Bn 279.75 Bn - 949,738.67
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 5.87 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 7.32 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 40.00 Mn
9 Revolution Medicines 37.78 Bn 37.78 Bn - 746.94 Mn
10 Adagene 198.85 Mn 198.85 Mn - -205.12 Bn

Historic Data

Download Data
DateValue
Dec 31, 2025 -205.12 Bn
Dec 31, 2024 38.74 Mn
Dec 31, 2023 45.17 Mn
Jun 30, 2023 -27.68 Bn
Dec 31, 2022 -28.65 Bn
Jun 30, 2022 -29.80 Bn
Dec 31, 2021 32.86 Mn
Jun 30, 2021 31.58 Mn
Dec 31, 2020 19.11 Mn
Dec 31, 2019 8.70 Mn